- Trials with a EudraCT protocol (53)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
53 result(s) found for: Dry cell.
Displaying page 3 of 3.
EudraCT Number: 2011-006322-25 | Sponsor Protocol Number: SPD602-301 | Start Date*: 2012-10-08 | |||||||||||
Sponsor Name:Shire Development LLC | |||||||||||||
Full Title: A Phase 2, Open-label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using SSP-004184 (SPD602). | |||||||||||||
Medical condition: Patients with transfusional iron overload due to hereditary anemias such as sickle cell disease, beta-thalassemia and Diamond-Blackfan anemia; aquired anemias such as Myelodysplastic Syndrome and o... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002499-16 | Sponsor Protocol Number: TMC125-C214 | Start Date*: 2006-12-22 | |||||||||||
Sponsor Name:Janssen R&D Ireland | |||||||||||||
Full Title: Early Access of TMC125 in combination with other antiretrovirals in treatment-experienced HIV-1 infected subjects with limited treatment options. | |||||||||||||
Medical condition: HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002843-26 | Sponsor Protocol Number: HO132AML/SAKK30/13 | Start Date*: 2014-03-27 | ||||||||||||||||
Sponsor Name:HOVON Foundation | ||||||||||||||||||
Full Title: Randomized study with a run-in dose-selection phase to assess the added value of lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients ... | ||||||||||||||||||
Medical condition: previously untreated acute myeloid leukemia (AML) or high risk myelodysplasie (MDS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) BE (Prematurely Ended) LT (Prohibited by CA) SE (Ongoing) FI (Prematurely Ended) DE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004839-23 | Sponsor Protocol Number: CA-4948-102 | Start Date*: 2023-02-09 | ||||||||||||||||
Sponsor Name:Curis, Inc | ||||||||||||||||||
Full Title: A Phase 1/2a, Open-Label Dose Escalation and Cohort Expansion Study of Orally Administered CA-4948(IRAK4i) as a Monotherapy in patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome a... | ||||||||||||||||||
Medical condition: Acute Myelogenous Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) PL (Completed) FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003458-13 | Sponsor Protocol Number: AFX01_201 | Start Date*: 2009-03-18 | |||||||||||
Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd. | |||||||||||||
Full Title: A Phase 2 Study of the Safety and Efficacy of AF37702 Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Subjects Previously Treated With Epoetin | |||||||||||||
Medical condition: Anaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002596-10 | Sponsor Protocol Number: INCB54828-203 | Start Date*: 2017-01-30 |
Sponsor Name:Incyte Corporation | ||
Full Title: A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement | ||
Medical condition: Lymphoid or myeloid neoplasm with 8p11 rearrangement known to lead to FGFR1 activation | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) AT (Completed) ES (Ongoing) BE (Completed) IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000435-45 | Sponsor Protocol Number: Ver-A-T1D | Start Date*: 2021-03-24 | |||||||||||
Sponsor Name:Medical University of Graz | |||||||||||||
Full Title: A randomised, double-blind, placebo controlled, parallel group, multi-centre trial in adult subjects with newly diagnosed type 1 diabetes mellitus investigating the effect of Verapamil SR on preser... | |||||||||||||
Medical condition: Type 1 diabetes mellitus(T1DM) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) AT (Ongoing) BE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003063-26 | Sponsor Protocol Number: 1634 | Start Date*: 2023-08-10 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC) | |||||||||||||
Full Title: Personalized Risk-Adapted Therapy in Post-Pubertal Patients with Newly Diagnosed Medulloblastoma (PersoMed-I) | |||||||||||||
Medical condition: Newly Diagnosed Medulloblastoma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) DE (Trial now transitioned) IT (Prematurely Ended) FR (Prematurely Ended) NL (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004940-27 | Sponsor Protocol Number: AIC316-03-II-01(Phase3) | Start Date*: 2022-01-05 |
Sponsor Name:AiCuris Anti-infective Cures GmbH | ||
Full Title: A randomized, open-label, multi-center, comparative trial, to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of acyclovir-resistant mucocutaneous HSV infections in ... | ||
Medical condition: Acyclovir-resistant mucocutaneous HSV infections in immunocompromised subjects | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004287-30 | Sponsor Protocol Number: LAL-CL06 | Start Date*: 2014-06-19 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals inc | |||||||||||||
Full Title: A Multicenter, Open-Label Study of Sebelipase Alfa in Patients with Lysosomal Acid Lipase Deficiency | |||||||||||||
Medical condition: Lysosomal Acid Lipase Deficiency (LALD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) ES (Completed) GB (Completed) IT (Prematurely Ended) DE (Completed) BE (Completed) HR (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000780-40 | Sponsor Protocol Number: D5740C00002 | Start Date*: 2014-11-11 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients | |||||||||||||
Medical condition: Anemia in chronic kidney disease patients with dialysis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) CZ (Completed) SK (Completed) HU (Completed) ES (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001521-25 | Sponsor Protocol Number: NEOMERO-2 | Start Date*: 2011-12-15 | |||||||||||
Sponsor Name:FONDAZIONE PENTA ONLUS | |||||||||||||
Full Title: Pharmacokinetics and safety of Meropenem in infants below 90 days of age (inclusive) with probable and confirmed meningitis: a European multicenter phase II trial | |||||||||||||
Medical condition: Bacterial meningitis in children up to 90 days of age | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) GR (Completed) LT (Completed) ES (Completed) NL (Completed) GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003265-17 | Sponsor Protocol Number: S63466 | Start Date*: 2020-09-10 | |||||||||||
Sponsor Name:Universitair Ziekenhuis Leuven (UZ Leuven) | |||||||||||||
Full Title: Phase II, dose ranging, efficacy study of anti-thymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes (T1D) | |||||||||||||
Medical condition: Type 1 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) FI (Completed) SI (Completed) AT (Completed) IT (Completed) DK (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
